Rhapsido in Egypt

Rhapsido - overview

Adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines. It is an Oral BTK inhibitor (tablet, twice daily) approved by the US FDA in 2025 and may be accessible to patients in Egypt through a Named Patient Program or personal-import pathway.

Access in Egypt

Egypt's EDA permits personal-use import of non-registered drugs under physician supervision; process is paperwork-heavy but viable.

How Reserve Meds coordinates access in Egypt

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Egypt-specific eligibility.
3. Treating physician in Egypt issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Rhapsido from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Egypt.

Typical timeline for Egypt

End-to-end, most requests are completed in 2-6 weeks. Egypt's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Egypt ask

• Is the pathway legal in Egypt? Yes - it operates under Egypt's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Egypt able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Rhapsido in Egypt

Join the Rhapsido waitlist